Invizius
Edinburgh
About Invizius
Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. Invizius develops H-Guard, an advanced hemocompatible coating capable of preventing foreign body reactions in the blood at the source. Invizius aims to revolutionize dialysis and other extracorporeal treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.8M
- Last round: Series Unknown (Sep 2024)
- Website: invizius.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/invizius-30481 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.